Dear Ms. Bell:

Please refer to your supplemental new drug applications S-032 and S-002 for Keppra® (levetiracetam) Tablets and Oral Solution.

These "Changes Being Effected" supplemental new drug applications provide for revised language to the Postmarketing Experience section of labeling to read as follows:

In addition to the adverse experiences listed above, the following have been reported in patients receiving marketed Keppra® worldwide. The listing is alphabetized: leukopenia, neutropenia, pancreatitis, pancytopenia (with bone marrow suppression identified in some of these cases) and thrombocytopenia. Alopecia has been reported with Keppra use; recovery was observed in the majority of cases where Keppra was discontinued. These adverse experiences have not been listed above, and data are insufficient to support an estimate of their incidence or to establish causation.

We have completed our review of these applications, as amended. These applications are approved, effective on the date of this letter.

The final printed labeling (FPL) must be identical to the proposed language contained in your submission dated October 1, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplements NDA 21-035/S-032 and NDA 21-505/S-002". Approval of this submission by FDA is not required before the labeling is used.

In addition, you must submit the content of labeling in electronic format as described in 21 CFR 314.50(l)(5). Current guidance for industry specifies that the content of labeling should be provided in PDF or SPL file format. This new submission requirement was published on December 11, 2003 (68 FR 69009) and was effective June 8, 2004. For additional information, consult the following guidance for industry: Regulatory Submissions in Electronic Format – Content of Labeling (February 2004).
In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Melina Griffis, R.Ph., Regulatory Project Manager, at (301) 594-5526.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Russell Katz
10/26/04 02:50:30 PM